CVM News and Press, Cel-Sci Corporation From 04/28/23

2023-04-28 04:52:47 ET Phase 3 cancer immunotherapy company, CEL-SCI ( NYSE: CVM ) prices an underwritten confidentially marketed public offering of 794,117 shares at an offering price of $1.70 per share. The closing of the offering is expected to take place on or about May 2,...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.7...

2023-04-19 15:06:14 ET CEL-SCI Corporation ( NYSE: CVM ) added ~15% Wednesday on above-average volume after disclosing a potential regulatory path to secure conditional approval in Canada for its lead asset, Multikine, targeted at patients with head & neck cancer. The bi...

Follows pre-submission meeting with Canada’s regulator Health Canada Plans to pursue marketing approval in other countries while preparing its BLA application for U.S. FDA CEL-SCI Corporation (NYSE American: CVM) today announced it has held a productive pr...

2023-03-21 07:15:07 ET Summary All good cons require great stories; without suggesting that CEL-SCI is a con, its great story has led investors far astray. CEL-SCI's financial metrics are problematic with its constrained liquidity. CEL-SCI's most pressing existential issue rev...

Presented at the 10th European Congress on Head & Neck Oncology Six Different Efficacy Measures Demonstrate Benefits of Adding Multikine to Standard of Care for Patients Who Have Not Had New Therapy Options in Decades CEL-SCI Corporation (NYSE American: CVM) ...

CEL-SCI Corporation (NYSE American: CVM) today announced it will present new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN), on March 8, 2023 at the 10th European Congress on He...

Cel-Sci press release ( NYSE: CVM ): Q1 GAAP EPS of -$0.18 beats by $0.01 . As of December 31, 2022, CEL-SCI had $18 million in cash and cash equivalents. For further details see: Cel-Sci GAAP EPS of -$0.18 beats by $0.01

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments. Clinical and Corporate Developments include: Multikine completely cleared cancer in 5 people with advanced head and ...

Cel-Sci press release ( NYSE: CVM ): FY net operating loss of ~$36.1M for the twelve months ended September 30, 2022, of which ~$11.4M was non-cash expense including stock-based employee compensation and ~$3.8M in depreciation and amortization expense while cash spent was $18.2M. ...